lefcar l-carnitine iv by glaxosmithkline L Carnitine l-Carnitine | Drugs | Springer

For PCa, dysregulated FA metabolism, which is mechanistically linked to aberrant AR and/or SREBP signaling (144), has multiple candidate factors for pharmacological inhibition, including SREBP (fatostatin) (145), acetyl-CoA carboxylase (ND-646, GS-0976) (146, 147), and SCD1 (Merck Frosst Cpd 3) (148)

Lu YB, Kobayashi K, Ushikai M, Tabata A, Iijima M, Li MX et al (2005) Frequency and distribution in East Asia of 12 mutations identified in the SLC25A13 gene of Japanese patients with citrin deficiency

The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism

we used a random-effect model and a profound improvement in LVEF was observed in patients who received L-C therapy (WMD: 4.14%, 95% CI: 2.34 to 5.93, P = 0.01, Figure 5(a))

Experiments that were designed to specifically inhibit PP2A were shown to prevent the effects of ceramide on AKT/PKB in a number of different cell types